Condition
SARS-CoV-2 Vaccination
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Unknown3
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04826770UnknownPrimary
Adaptive Immune Response to COVID-19 Vaccination
NCT05490342CompletedPrimary
Effect of SARS-CoV-2 Vaccination in Liver Transplant Recipients
NCT05145348Unknown
Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome.
NCT05171959UnknownPrimary
Platelet and Immune Response in Covid-19 Vaccine
NCT05165719Completed
Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccination
Showing all 5 trials